http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
HPLC법을 이용한 효소처리스테비아의 분석법 개선 연구
윤소정(Sojeong Yoon),홍성준(Seong Jun Hong),조성민(Seong Min Jo),정향연(Hyangyeon Jeong),조승목(Suengmok Cho),이양봉(Yang Bong Lee),신의철(Eui-Cheol Shin) 한국식품영양과학회 2023 한국식품영양과학회지 Vol.52 No.4
본 연구는 효소처리스테비아 분석법에 대한 개선시험법을 제시하는 연구로써 기존 JECFA에서 제시한 6종의 효소처리스테비아 분석법을 기본으로 하여 13종의 효소처리스테비아의 동시 분석을 진행하였다. 13종의 효소처리스테비아의 분석은 method validation을 통해 타당성을 제시하였고, 서로 다른 세 곳의 분석 기관에서의 동시 분석을 통해 기관별 오차, 분석일차, 그리고 분석자의 차이에 의해서도 타당한 결과를 얻을 수 있었다. 이에 대한 실험을 통해 상업용 효소처리스테비아 제품의 적용을 진행하여 13종 중 11종의 효소처리스테비아 배당체가 정량 및 정성이 이루어졌다. 이에 본 연구에서 제시된 시험법을 근거로 하여 공인된 효소처리스테비아의 정량 및 정성 연구의 체계화가 가능한 것으로 보인다. This study conducted experiments under varied conditions using high performance liquid chromatography (HPLC) to improve the enzymatically modified stevia analysis method presented at the Joint FAO/WHO Expert Committee on Food Additives. The modified method was thereafter applied for the analysis of enzyme-treated stevia. HPLC was equipped with an NH2 column, acetonitrile, and water as the mobile phase, and the flow rate was adjusted to 0.5 mL/min. Each limit of detection and limit of quantitation was analyzed for method validation. Precision and repeatability were also analyzed and were determined to be within the guideline range. Totally, 13 enzymatically modified stevia were separated by HPLC chromatogram. Commercial products were subsequently analyzed using the improved method, and 11 types of enzymatically modified stevia were detected. Our results validate that the improved method can officially be applied for testing enzymatically modified stevia.
성인 단장증후군 환자의 다학제 장 재활: 국내 단일 기관 다학제 장재활 클리닉의 경험
윤소정 ( Sojeong Yoon ),이상훈 ( Sanghoon Lee ),박효정 ( Hyo Jung Park ),김현정 ( Hyun-jung Kim ),윤지혜 ( Jihye Yoon ),민자경 ( Ja-kyung Min ),서정민 ( Jeong-meen Seo ) 한국정맥경장영양학회 2018 한국정맥경장영양학회지 Vol.10 No.2
Purpose: Intense multidisciplinary team effort is required for the intestinal rehabilitation of patients afflicted with the short bowel syndrome (SBS). These include enteral and parenteral nutrition (PN) support, monitoring of complications related to treatment, and considering further medical or surgical options for intestinal adaptation. Methods: In the Intestinal Rehabilitation Team (IRT) at the Samsung Medical Center, we have experienced 20 cases of adult SBS requiring multidisciplinary intestinal rehabilitation. This study is a retrospective review of the collected medical records. Results: Of the 20 subjects treated, 12 patients were male and 8 patients were female. At the time of referral to the IRT, the mean age was 51.5 years, and the mean body weight was 50.1 kg, which was 90% of the usual body weight. The diseases or operative managements preceding massive bowel resection were malignancy in 11 cases, cardiac surgery in 2 cases, trauma in 2 cases and one case, each of tuberculosis, corrosive esophagitis, atrial fibrillation, simultaneous pancreas and kidney transplantation, and perforated appendicitis. Of these, there were 14 survivals and 6 mortalities. The fatalities were attributed to progression of disease, intestinal failure-associated liver disease, and sepsis (unrelated to intestinal failure) (2 cases each). Among the 14 surviving patients, 8 patients have been weaned off PN, whereas 6 are still dependent on PN (mean PN dependence 36%). Conclusion: This paper reports the results of multidisciplinary intestinal rehabilitation of adult short bowel patients treated at the Samsung Medical Center. Further studies are required to improve survival and enteral tolerance of these patients.
Screening of potential probiotic and anti-diabetic activities of Lactobacillus spp. from kimchi
Sojeong Kim,Wonyoung Cho,Hyunah Jang,Jiwon Yoon,Misook Kim 한국식품영양과학회 2021 한국식품영양과학회 학술대회발표집 Vol.2021 No.10
The research on novel probiotic bacteria has been increased with the market expansion of the global health functional food and medicine. In this study, we screened two Lactobacillus pentosus HA4-CK and JW32-CK, and a Lactobacillus plantarum HA30-CK from kimchi, and evaluated their probiotic activities and inhibition against carbohydrate hydrolyzing enzymes. Through the 16s rRNA gene sequencing, they revealed similarities with L. pentosus DSM 20314 of 99.65% for HA4-CK and 99.79% for JW32-CK, and L. plantarum ATCC 14917 of 99.79% for HA30-CK. Our selected strains, HA4-CK, HA30-CK, and JW32-CK survived more than 50% when they incubated in each 0.1% pepsin and 0.3% bile salt solution at 37℃ for 3h. They showed negative reactions in β-hemolysis tests. All selected strains inhibited the growth of Escherichia coli, E. coli O157:H7, Bacillus cereus, and Staphylococcus aureus. They showed strong α-glucosidase inhibitory activity and weak α-amylase inhibitory activity compared to acarbose. Therefore, our finding strains might be useful alternatives to prevent diabetes as well as to improve intestinal balance.
Yi, SoJeong,Kim, Tae-Eun,Yoon, Seo Hyun,Cho, Joo-Youn,Shin, Sang-Goo,Jang, In-Jin,Yu, Kyung-Sang Lippincott Williams Wilkins, Inc. 2011 Journal of cardiovascular pharmacology Vol.57 No.6
AIM:: Fimasartan (BR-A-657) is a new angiotensin II receptor antagonist used as antihypertensive agent. The objective of this study was to investigate the effect of the coadministration of fimasartan and amlodipine on the steady-state pharmacokinetics of each drug. METHODS:: This study comprised 2 separate parts, A and B; each was a multiple-dose, open-label, 2-period crossover study in healthy male volunteers. In part A, 20 subjects were administered 120 mg of fimasartan alone in period I and fimasartan with 10 mg of amlodipine in period II. In part B, 14 subjects were administered amlodipine alone, followed by coadministration with fimasartan. Blood samples for pharmacokinetics were collected up to 24 hours after the last dosing. The pharmacokinetics of the coadministration of fimasartan and amlodipine were compared with that of each drug alone. RESULTS:: The geometric mean ratio and 90% confidence intervals for Cmax,ss and area under the plasma concentration-time curve (AUC)&tgr;,ss of fimasartan (with/without amlodipine) were 1.096 (0.746-1.610) and 1.163 (1.001-1.351), respectively. The geometric mean ratios (90% confidence interval) for Cmax,ss and AUC&tgr;,ss of amlodipine (with/without fimasartan) after coadministration with fimasartan were 1.037 (0.969-1.110) and 0.975 (0.920-1.033), respectively. CONCLUSIONS:: Coadministration of fimasartan and amlodipine did not result in clinically relevant changes in the systemic exposure of fimasartan or amlodipine.
Yi, SoJeong,Jeon, Hyewon,Yoon, Seo Hyun,Cho, Joo-Youn,Shin, Sang-Goo,Jang, In-Jin,Yu, Kyung-Sang Lippincott Williams Wilkins, Inc. 2012 Journal of cardiovascular pharmacology Vol.59 No.4
ABSTRACT:: Tolvaptan is a selective arginine vasopressin V2-receptor antagonist that is used as an aquaretic agent. This trial investigated the pharmacokinetics and pharmacodynamics of 15- to 60-mg single oral doses of tolvaptan in healthy Korean men. A dose block–randomized, placebo-controlled, double-blind, single ascending dose trial was conducted with 46 subjects receiving tolvaptan (15, 30, or 60 mg) or placebo. To determine pharmacokinetics and pharmacodynamics, blood and urine samples were collected at baseline and up to 48 hours after drug administration. Urine volume and fluid intake were measured for 24 hours starting the day before dosing (day −1) as baseline, and on the day of drug administration (day 1). Tolvaptan showed dose-linear pharmacokinetic characteristics regarding area under the concentration–time curve. Changes from baseline in 24-hour urine volume and 24-hour fluid balance correlated significantly with area under the concentration–time curve from time 0 to the last measurable time. Dose-dependent increases were observed in serum osmolality, serum sodium concentration, and free water clearance in the 4- to 8-hour interval after dosing, and these increases were maintained for at least 24 hours. Single 15- to 60-mg doses of tolvaptan exhibited linear pharmacokinetics and resulted in substantial, dose-dependent aquaresis in healthy Korean men.
Yi, SoJeong,Kim, Sung Eun,Park, Min-Kyu,Yoon, Seo Hyun,Cho, Joo-Youn,Lim, Kyoung Soo,Shin, Sang-Goo,Jang, In-Jin,Yu, Kyung-Sang Adis International 2012 BioDrugs Vol.26 No.3
<P>HD203 is a biosimilar of etanercept, a fusion protein of the ligand-binding portion of the human tumor necrosis factor receptor II linked to the Fc portion of human immunoglobulin G1. Since HD203 is under clinical development, this study was conducted to compare the pharmacokinetics of HD203 with Enbrel®, the first marketed etanercept.</P>